Relapse in leukemia tied to mutations that persist through treatment

in to that
Senior author Timothy J. Ley, a professor of oncology, says most patients diagnosed with acute myeloid leukemia (AML) "fall into a gray area" when doctors try to predict their risk of relapse. "About 80% of AML patients go into remission with …
Read more on Medical News Today

Hybrigenics gets Orphan Drug designation for the treatment of Acute Myeloid
Leukemia Hybrigenics (ALHYG), a French bio-pharmaceutical company with a focus on research and development of new treatments against proliferative diseases, has announced that the Food and Drug Administration (FDA) has granted Orphan Drug …

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow
The TP53 mutation is frequently detected in acute myeloid leukemia (AML) patients with complex karyotype (CK), but the stability of this mutation during the clinical course remains unclear. In this study, TP53 mutations were identified in 7% of 500 …

Check Also

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods – CancerConnect News : CancerConnect News

Following standard therapy for early breast #cancer, women undergo tests and scans to ensure that ...

Leave a Reply

Your email address will not be published. Required fields are marked *